DPP4 and Hypoglycemia: In another randomized controlled study, compared with the metformin-glimepiride combination (metformin- sulphonylureas), the combination of metformin-gemigliptin (metformin-DPP-4 inhibitor) achieved more effective glycemic control in T2D patients without increasing the risk of hypoglycemia or weight gain, which may be related to improvements in gut microbiota (108).